List of Excipients in Branded Drug OPILL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
L Perrigo Company	OPILL	norgestrel	0113-8101	CELLULOSE, MICROCRYSTALLINE	2026-07-13
L Perrigo Company	OPILL	norgestrel	0113-8101	FD&C YELLOW NO. 5	2026-07-13
L Perrigo Company	OPILL	norgestrel	0113-8101	LACTOSE MONOHYDRATE	2026-07-13
L Perrigo Company	OPILL	norgestrel	0113-8101	MAGNESIUM STEARATE	2026-07-13
L Perrigo Company	OPILL	norgestrel	0113-8101	POLACRILIN POTASSIUM	2026-07-13
Redpharm Drug	OPILL	norgestrel	67296-1938	CELLULOSE, MICROCRYSTALLINE	2026-07-13
Redpharm Drug	OPILL	norgestrel	67296-1938	FD&C YELLOW NO. 5	2026-07-13

Opill Excipient Strategy and Commercial Opportunities for Norgestrel OTC Contraception

Last updated: September 4, 2026

Opill is the first U.S. nonprescription daily oral contraceptive. Its active ingredient is norgestrel 0.075 mg, a progestin previously marketed by prescription as Ovrette. Perrigo’s commercial opportunity is based primarily on OTC access, brand distribution, adherence, and channel expansion rather than a new chemical entity patent estate. The excipient platform is relatively conventional, which creates limited composition-of-matter differentiation but leaves room for improvements in swallowability, stability, packaging, and patient adherence. [1][2]

What is Opill and how does its formulation work?

Opill is a progestin-only oral contraceptive tablet containing 0.075 mg of norgestrel. The FDA approved the prescription-to-OTC switch in July 2023. Perrigo began U.S. commercial distribution in 2024 through retail and online channels. [1][3]

What is the active pharmaceutical ingredient in Opill?

Attribute	Opill
Active ingredient	Norgestrel
Strength	0.075 mg per tablet
Dosage form	Immediate-release oral tablet
Therapeutic category	Progestin-only contraceptive
U.S. regulatory status	Nonprescription
Sponsor	Perrigo Company plc
Prescription predecessor	Ovrette
FDA application	NDA 017031
Administration	One tablet daily at approximately the same time

Opill suppresses ovulation and produces additional contraceptive effects through changes in cervical mucus and the endometrium. Unlike combined oral contraceptives, it does not contain estrogen. The absence of estrogen supports use by some consumers who cannot or do not want to use estrogen-containing contraception. [1]

What excipients are used in Opill?

Public U.S. labeling identifies Opill as containing common tablet excipients, including lactose monohydrate, corn starch, magnesium stearate, and povidone. The excipients support tablet formation, disintegration, lubrication, and manufacturability. [2]

Excipient	Primary technical function	Commercial relevance
Lactose monohydrate	Diluent and tablet-volume carrier	Potential allergen and intolerance communication issue; supports low-dose API blending
Corn starch	Diluent and disintegrant	Supports tablet breakup and low-cost manufacture
Povidone	Binder	Supports granule and tablet strength
Magnesium stearate	Lubricant	Improves ejection and reduces manufacturing friction

The low norgestrel dose makes content uniformity a central formulation requirement. Excipients must support homogeneous distribution of the active ingredient at a 0.075 mg strength without creating excessive tablet weight or segregation during processing.

What excipient strategy does Opill use?

Opill’s apparent formulation strategy is a conventional, cost-efficient immediate-release tablet platform. The commercial advantages are manufacturing familiarity, broad excipient availability, and a relatively low regulatory burden for well-characterized inactive ingredients.

How does the formulation address a low-dose API?

Low-dose hormonal products create several technical risks:

• API segregation during blending or transfer.
• Assay variability between tablets.
• Content-uniformity failures.
• Over-lubrication from excessive magnesium stearate.
• Slower disintegration if compression or hydrophobic lubrication is poorly controlled.
• Stability loss from moisture, heat, or light exposure.

A formulation using lactose, starch, povidone, and magnesium stearate can address these risks through controlled particle-size distribution, geometric dilution, wet or dry granulation, and validated blend-uniformity controls.

Povidone can improve granule cohesion, while starch helps tablet disintegration. Magnesium stearate must be controlled because excessive blending can reduce tablet wettability and delay dissolution. Lactose provides bulk for the low-dose active ingredient, but the sponsor must manage moisture exposure and consumer labeling considerations.

Does Opill use a controlled-release or novel delivery system?

No. Opill is an immediate-release oral tablet rather than a controlled-release system, transdermal product, implant, vaginal ring, or long-acting injectable. This limits formulation-patent differentiation but reduces production complexity and supports broad OTC distribution.

What commercial opportunities exist for Opill excipients?

The strongest opportunities are in incremental formulation improvements rather than replacement of the core product. A new excipient platform would need to produce a measurable benefit in stability, adherence, manufacturing yield, consumer acceptability, or regulatory positioning.

Which excipient improvements have the highest commercial value?

Opportunity	Potential benefit	Patent potential	Commercial assessment
Lactose-free formulation	Expands use among lactose-sensitive consumers	Moderate	Strong consumer-marketing opportunity
Smaller tablet	Improves swallowing and adherence	Moderate	Attractive if bioequivalence is maintained
Rapid-disintegration tablet	Supports ease of administration	Moderate	Useful for adherence but not necessarily essential
Taste-masked or orally disintegrating tablet	Supports consumers with swallowing difficulty	Moderate to high	Requires careful stability and dose-uniformity work
Moisture-protective formulation	Improves shelf life and distribution resilience	Low to moderate	Relevant for e-commerce and high-temperature markets
Direct-compression platform	Reduces processing steps	Low	Mainly a cost and manufacturing opportunity
Film-coated tablet	Improves handling, taste, and appearance	Low to moderate	May raise tablet size and process cost
Unit-dose blister packaging	Improves daily compliance	Moderate	Stronger commercial value than a minor excipient change
Calendar-pack presentation	Supports adherence and retail differentiation	Moderate	Useful for OTC consumers
Pediatric or adolescent-friendly format	Broadens future market positioning	High regulatory complexity	Potential long-term opportunity

An excipient change alone may not justify a separate commercial product. The strongest value generally comes from pairing the formulation change with a new dosage form, packaging system, consumer segment, or geographic market.

What formulation patents could protect future Opill products?

A future Opill formulation patent would need to claim more than the use of standard excipients in a routine tablet. The most defensible claim categories would include:

What excipient combinations could support patent protection?

Potential claim concepts include:

1. A specific norgestrel-to-excipient ratio that improves content uniformity.
2. A lactose-free blend that maintains dissolution and stability.
3. A low-moisture formulation with defined water activity.
4. A rapidly disintegrating tablet meeting specified disintegration and dissolution limits.
5. A taste-masked tablet with a defined coating or matrix system.
6. A formulation that maintains potency after accelerated temperature and humidity exposure.
7. A manufacturing process that reduces norgestrel segregation.
8. A blister-pack and tablet combination that improves product stability or adherence.

Patent strength would depend on comparative data. A claim covering ordinary lactose, starch, povidone, and magnesium stearate would likely face obviousness and lack-of-inventiveness challenges unless the formulation produced an unexpected result.

Could excipient patents delay generic Opill entry?

Usually, excipient patents have limited ability to block all generic entry. A generic sponsor may design around a formulation claim by using different diluents, binders, disintegrants, lubricants, or manufacturing methods.

A stronger barrier would combine:

• A narrow but technically necessary formulation claim.
• Demonstrated superiority in dissolution or stability.
• A method-of-use claim tied to OTC adherence or a defined consumer population.
• A packaging claim covering a required stability system.
• Manufacturing controls that are difficult to reproduce economically.

Even then, a generic could enter with a different formulation if it demonstrates pharmaceutical equivalence, bioequivalence, and compliance with applicable FDA requirements.

What is the Orange Book status of Opill?

Opill’s central exclusivity position is regulatory and commercial, not a visible new chemical entity patent position. FDA Orange Book records should be reviewed for current patent listings, exclusivity codes, and any later-approved supplements. The original norgestrel product has a long prescription history, which makes a new active-ingredient exclusivity theory unavailable for the OTC product. [4]

When does Opill lose exclusivity?

The FDA’s OTC switch approval may receive regulatory exclusivity linked to the sponsor’s clinical investigations and application-specific work. The duration and scope depend on the exclusivity code recorded by FDA and the approved application history.

Opill does not receive a fresh five-year new chemical entity exclusivity period because norgestrel is an established active ingredient. The relevant competitive barriers are therefore:

• Any remaining FDA regulatory exclusivity.
• Any listed patents.
• Product-specific formulation or manufacturing rights.
• Brand recognition and retail placement.
• Consumer trust in an OTC contraceptive product.
• Distribution and supply reliability.

The existence of an OTC product does not prevent another company from pursuing an abbreviated or other FDA pathway for a comparable norgestrel product once applicable regulatory barriers expire.

Which companies are challenging Opill or competing with it?

The competitive field includes established oral contraceptives, emergency contraception, prescription telehealth providers, condoms, long-acting reversible contraceptives, and future OTC hormonal products.

Competitor category	Representative products or companies	Competitive effect
Combined oral contraceptives	Generic ethinyl estradiol/progestin products	Lower price; estrogen contraindications limit substitution
Progestin-only contraception	Generic norethindrone products	Prescription access remains a barrier
Emergency contraception	Plan B, Take Action, generic levonorgestrel	Different use case; does not replace daily contraception
Long-acting contraception	Nexplanon, intrauterine systems	Higher efficacy and duration but requires clinician involvement
Barrier methods	Condom manufacturers and retailers	OTC access and low upfront cost
Digital reproductive-health providers	Telehealth companies and pharmacies	Compete on access, counseling, subscriptions, and fulfillment
Future OTC contraceptives	Potential manufacturers of other progestin products	Could expand the category and pressure pricing

No biosimilar pathway applies because Opill is a small-molecule drug, not a biologic. The relevant competitive pathway is generic or hybrid drug approval, not biosimilar approval.

What generic launch risks exist for Opill?

Generic entry could occur through an abbreviated application if a sponsor can establish the required pharmaceutical equivalence and bioequivalence. The commercial timing would depend on Orange Book listings, FDA exclusivity, application review, manufacturing capacity, and OTC labeling requirements.

What could delay a generic Opill launch?

A generic sponsor may face:

• Difficulty reproducing low-dose content uniformity.
• Need for comparative dissolution across multiple media.
• Manufacturing scale-up problems.
• Packaging requirements for moisture and temperature control.
• OTC label comprehension and actual-use evidence, depending on the pathway.
• Retail and e-commerce distribution costs.
• Limited margin at low consumer prices.
• Need to establish trust in a sensitive therapeutic category.

A Paragraph IV certification would be relevant only if an applicable patent is listed in the Orange Book. If no blocking patent is listed, competition would instead turn on regulatory exclusivity and application approval. A Paragraph IV filing could trigger patent litigation, a 30-month stay in appropriate circumstances, and possible settlement negotiations under the Hatch-Waxman framework. [5]

What patent litigation affects Opill?

Publicly visible risk is more likely to involve future formulation, packaging, or manufacturing patents than a surviving compound patent for norgestrel. Potential disputes could involve:

• Tablet composition.
• Dissolution specifications.
• Blister-pack materials.
• Stability claims.
• Manufacturing processes.
• OTC label language.
• Use in defined populations.
• Agreements between Perrigo and future generic applicants.

A settlement could establish an authorized-generic launch date, license rights, manufacturing rights, or restrictions on a competing formulation. Any assessment of litigation exposure should distinguish between a patent listed for Orange Book purposes and a non-listed patent that may support a conventional infringement action but does not automatically trigger a Paragraph IV stay.

How does Opill compare with other contraceptive commercial opportunities?

Opill’s value proposition is access. Its tablet platform is inexpensive and scalable, but it has lower formulation differentiation than products using long-acting delivery systems.

Factor	Opill	Long-acting implant	Combined oral contraceptive	Emergency contraception
OTC access	Yes	No	Generally no	Yes
Daily adherence required	Yes	No	Yes	No, episodic
Estrogen exposure	No	No	Usually yes	No
Manufacturing complexity	Low to moderate	High	Low to moderate	Low
Excipient differentiation	Moderate opportunity	High	Moderate	Moderate
Main commercial moat	Access and brand	Device and clinical infrastructure	Brand, price, and distribution	Speed and availability

The most attractive near-term commercial extensions are calendar packaging, subscription fulfillment, smaller tablets, and formulations that reduce consumer concerns about excipients. A new active ingredient or long-acting presentation would offer greater patent potential but would require materially higher development and regulatory investment.

What manufacturing and geographic opportunities exist?

Opill’s excipient supply chain can use widely available pharmaceutical-grade materials. That supports contract manufacturing and regional production, but it also reduces supply-chain exclusivity.

Which geographic markets offer expansion potential?

The primary expansion opportunity is outside the United States in markets where:

• Oral contraceptives are already accepted.
• Pharmacist or nonprescription access is available.
• Norgestrel has an established regulatory history.
• Local labeling and reproductive-health rules permit direct consumer purchase.
• Distribution can support temperature and humidity requirements.

A global excipient strategy should account for lactose labeling, local permitted-excipient lists, pharmaceutical-grade starch requirements, and country-specific OTC classification. Packaging may require greater emphasis in tropical markets, where heat and humidity can accelerate degradation or compromise tablet performance.

What is the revenue exposure from Opill?

Opill revenue depends on U.S. category expansion rather than premium pricing alone. Key commercial variables include:

• Retail price relative to generic prescription contraception.
• Insurance reimbursement or lack of reimbursement.
• Online subscription retention.
• Pharmacy placement.
• Consumer awareness.
• Repeat purchase rates.
• Out-of-pocket affordability.
• Availability during public-health and access disruptions.

The product may carry a premium over generic prescription tablets because consumers pay for immediate access, privacy, and convenience. That premium can narrow if multiple OTC competitors enter the market.

How strong is the Opill patent estate?

The apparent estate is stronger commercially than chemically. Norgestrel is an established active ingredient, and conventional excipients do not create a durable composition-of-matter moat. The strongest defensible rights would likely concern newly developed formulations, packaging, manufacturing controls, or approved labeling.

Patent layer	Expected strength
Norgestrel compound patent	Weak or expired for current commercial purposes
Basic immediate-release tablet	Low
Standard excipient combination	Low to moderate
Novel low-dose uniformity formulation	Moderate
Stability-enhancing package	Moderate
Adherence-focused packaging	Moderate
New delivery system	Moderate to high
OTC regulatory exclusivity	Time-limited but commercially important

Key Takeaways

• Opill is a 0.075 mg norgestrel immediate-release OTC tablet.
• Its public formulation uses conventional excipients, including lactose monohydrate, corn starch, povidone, and magnesium stearate.
• The main formulation challenge is uniform delivery of a very low API dose.
• The strongest excipient opportunities are lactose-free, smaller, rapidly disintegrating, moisture-protected, or adherence-oriented products.
• Norgestrel’s established history limits new chemical entity patent protection.
• Generic entry risk depends on current Orange Book listings, FDA exclusivity, formulation patents, and approval timing.
• Paragraph IV litigation is relevant only if qualifying patents are listed and challenged.
• Opill is not subject to biosimilar competition.
• Packaging, retail access, subscriptions, and consumer adherence may create greater commercial value than a minor excipient change.
• A durable patent position would require comparative data showing unexpected stability, dissolution, content uniformity, or adherence benefits.

FAQs

Can a lactose-free Opill formulation be commercially differentiated?

Yes. A lactose-free formulation could address consumer preferences and intolerance concerns, but it would need to preserve content uniformity, dissolution, stability, and bioequivalence.

Could Opill be reformulated as an orally disintegrating tablet?

Yes, but the product would require development work addressing taste, dose uniformity, moisture sensitivity, mechanical strength, and FDA regulatory requirements.

Does Opill have biosimilar competition?

No. Norgestrel is a small-molecule active ingredient. Any comparable product would follow a generic or other small-molecule drug pathway.

Would a calendar blister pack receive patent protection?

Potentially. Protection would be stronger if the packaging system produced a measurable adherence, stability, or dispensing benefit rather than merely arranging tablets by day.

Can a generic use different excipients from Opill?

Yes. A generic sponsor generally may use a different excipient system if the product satisfies applicable pharmaceutical equivalence, bioequivalence, quality, labeling, and regulatory requirements.

References

1. U.S. Food and Drug Administration. (2023, July 13). FDA approves first nonprescription daily oral contraceptive. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive

2. U.S. National Library of Medicine. (2024). DailyMed: Opill norgestrel tablet labeling. https://dailymed.nlm.nih.gov/

3. Perrigo Company plc. (2024). Opill product information and commercialization materials. https://www.perrigo.com/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-resources